EUVIMEDEUVIMED entdecken
Studienprotokoll

Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [ 177 Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer

Louise Kostos, James P Buteau, Grace Kong, Ben Tran, Mohammad B Haskali, Michael Fahey, Megan Crumbaker, Louise Emmett, Michael S Hofman, Arun A Azad

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.269252 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Louise Kostos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; louise.kostos@petermac.org. Hauptthemen laut MEDLINE: Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantTaxoidsHumansMaleClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicNeoplasm MetastasisRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

177LuPSMAcombination therapyprostate cancerradiopharmaceutical therapytheranostics

Substanzen

cabazitaxelDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177PluvictoPSMA-617RadioisotopesTaxoidsProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; louise.kostos@petermac.org.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Radiopharmaceutical Production and Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Zitieren

APA

Kostos, L., Buteau, J. P., Kong, G., Tran, B., Haskali, M. B., Fahey, M., Crumbaker, M., Emmett, L., Hofman, M. S., & Azad, A. A. (2025). Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [ 177 Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.269252

Vancouver

Kostos L, Buteau JP, Kong G, Tran B, Haskali MB, Fahey M, et al. Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [ 177 Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.269252

BibTeX
@article{Kostos2025,
  author = {Kostos, Louise and Buteau, James P and Kong, Grace and Tran, Ben and Haskali, Mohammad B and Fahey, Michael and Crumbaker, Megan and Emmett, Louise and Hofman, Michael S and Azad, Arun A},
  title = {Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [ 177 Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.269252}
}
Kostenlos starten →